Global Initiative

DGAP-News: sterna biologicals announces dosing of first patient in phase IIa proof-of-concept study with SB010 in moderate to severe asthma

Retrieved on: 
Monday, December 20, 2021
Nitric acid, Hope, Global Initiative, Company, IIA, Hospital, Epigenetics of diabetes Type 2, LABA, The New England Journal of Medicine, Sterna, POC, Today, Pulmonology, Pharmacokinetics, Clinic, ICS, Inhalation, Safety, Inflammation, Patient, Global Initiative for Asthma, Ulcerative colitis, Hannover Medical School, Factor X, GINA, COPD, Bronchospasm, Atopic dermatitis, Immunomodulation, Chronic obstructive pulmonary disease, In Practice Systems Limited, Asthma, Deoxyribozyme, Gesellschaft mit beschränkter Haftung, Aquaculture, Pharmaceutical industry

"We are pleased that the first patient has been treated in our GIANT-1 trial with inhaled SB010 in patients with uncontrolled moderate to severe asthma," said Dr. Marion Wencker, Chief Medical Officer of sterna biologicals.

Key Points: 
  • "We are pleased that the first patient has been treated in our GIANT-1 trial with inhaled SB010 in patients with uncontrolled moderate to severe asthma," said Dr. Marion Wencker, Chief Medical Officer of sterna biologicals.
  • "I am excited about the potential SB010 holds in treating patients with moderate to severe uncontrolled asthma.
  • In this study, sterna will for the first time, combine pharmacological and digital therapy by integrating VisionHealth's Kata(R) Clinical into the trial.
  • Consequently, the Company's therapeutic candidates containing hgd40, SB010 and SB012, address several inflammatory processes simultaneously and rebalance an overall dysregulated immune response.

World Health Organization and St. Jude Children's Research Hospital to dramatically increase global access to childhood cancer medicines

Retrieved on: 
Monday, December 13, 2021
WHO, Global Alliance, Medicine, Degenerative disease, List, Global Initiative, World, World Health Organization, Access, Achievement, Health, Cancer, Science, Survival, International Society of Paediatric Oncology, Diagnosis, UN, Subaru Global Platform, Information, Department, International Society, CEO, National Cancer Intelligence Network, Global Initiative for Emergency and Essential Surgical Care, Parent, Research, Social media, St. Jude Children's Research Hospital, Childhood cancer, Pharmaceutical industry, Vaccine, Health insurance, Hospital, Jude the Apostle, Child, ST

GENEVA and MEMPHIS, Tenn., Dec. 13, 2021 /PRNewswire/ --The World Health Organization and St. JudeChildren's Research Hospital today announced plans to establish a platform that will dramatically increase access to childhood cancer medicines around the world.

Key Points: 
  • GENEVA and MEMPHIS, Tenn., Dec. 13, 2021 /PRNewswire/ --The World Health Organization and St. JudeChildren's Research Hospital today announced plans to establish a platform that will dramatically increase access to childhood cancer medicines around the world.
  • Experience the interactive Multichannel News Release here: https://www.multivu.com/players/English/8928751-world-health-organizatio...
    The Global Platform for Access to Childhood Cancer Medicines , the first of its kind, will provide an uninterrupted supply of quality-assured childhood cancer medicines to low- and middle-income countries.
  • World Health Organization and St. Jude Children's Research Hospital first collaborated in 2018, when St. Jude became the first WHO Collaborating Centre for Childhood Cancer and committed $15 million for the creation of the Global Initiative for Childhood Cancer.
  • In 2018, St. Jude and the World Health Organization launched the Global Initiative for Childhood Cancer to increase survival rates to 60% by 2030 for the most common forms of childhood cancer.

Aerogen® and CanSinoBIO agree on landmark development and commercial supply partnership for world’s first inhaled Covid-19 vaccine delivery

Retrieved on: 
Thursday, December 9, 2021
Technology, Mobile, Wireless, Medical Devices, Infectious Diseases, Clinical Trials, Biotechnology, Other Health, Health, Data Management, CanSino Biologics, ISO 10993, Risk, Research, COPD, NMPA, COVID19, Tidal volume, Adenoviridae, SSE, International Society, McLoughlin, Vaccine, Patient, Mechanical ventilation, Partnership, Atmosphere of Earth, Conditional, McGrath, CRM197, Mechanical, Use, Global Initiative, Ventilation, Multimedia, Effect, COVID-19, Public health, HKEX, Diagnosis, Chronic obstructive pulmonary disease, Noble gas, Pharmaceutical industry, Medical device

Following months of collaborative development work, Aerogen (Galway, Ireland) and CanSinoBIO (SSE: 688185, HKEX: 06185) (Tianjin, China) have announced a development and commercial supply partnership for the inhaled delivery of CanSinoBIOs Recombinant Novel Coronavirus Vaccine Convidecia utilizing Aerogens proprietary vibrating mesh aerosol drug delivery technology.

Key Points: 
  • Following months of collaborative development work, Aerogen (Galway, Ireland) and CanSinoBIO (SSE: 688185, HKEX: 06185) (Tianjin, China) have announced a development and commercial supply partnership for the inhaled delivery of CanSinoBIOs Recombinant Novel Coronavirus Vaccine Convidecia utilizing Aerogens proprietary vibrating mesh aerosol drug delivery technology.
  • Dr. Xuefeng YU, Chairman and Chief Executive Officer of CanSinoBIO commented; Our partnership with Aerogen started in 2013 and for almost a decade, weve been advancing the possibility of aerosol drug delivery.
  • The innovative development on the inhaled delivery of COVID-19 vaccine is the testimony of our collaborative efforts.
  • The Aerogen Solo is a closed-system, single-patient-use aerosol drug delivery technology3 that mitigates the transmission of patient-generated infectious aerosol during ventilation4-9.

Hologic’s COVID-19 Tests Detect Omicron Variant

Retrieved on: 
Tuesday, November 30, 2021
Research, Medical Devices, Women, Infectious Diseases, Genetics, General Health, Pharmaceutical, Consumer, Health, Science, Coronavirus, Genome, HOLX, Severe acute respiratory syndrome coronavirus 2, Virus, COVID-19, Omicron, Nasdaq, Panther, Infection, Global Initiative, Science, Medical imaging

Hologic, Inc. (Nasdaq: HOLX) announced today that its three SARS-CoV-2 tests all detect the recently emerged Omicron variant of the coronavirus that causes COVID-19.

Key Points: 
  • Hologic, Inc. (Nasdaq: HOLX) announced today that its three SARS-CoV-2 tests all detect the recently emerged Omicron variant of the coronavirus that causes COVID-19.
  • Initially identified in South Africa and subsequently in a number of African, European and North American countries, the Omicron variant (B.1.1.529) contains approximately 30 mutations.
  • We designed our assays with this in mind, and as a result, we are confident that the Omicron variant will not impact the performance of our assays.
  • Aptima and Panther Fusion tests run on Hologics fully automated Panther and Panther Fusion systems, respectively, which provide initial results in approximately three hours and can process more than 1,000 tests in 24 hours.

Canada, Mexico & US Kickstart Global Renewable Energy Transition for Remote & Indigenous Communities

Retrieved on: 
Thursday, November 4, 2021
Knowledge, People, Commission, Indigenous self-government in Canada, Global Initiative, Commission for Environmental Cooperation, Electricity, SEMARNAT, COP26, United States Environmental Protection Agency, International Renewable Energy Agency, ECCC, EPA, Water quality, Multimedia, United Nations Global Initiative to Fight Human Trafficking, Natural Resources, Government, IRENA, Natural Resources Canada, Environment, Solution, ICE, CEC, Council, NAFTA, Climate change, Nordic Investment Bank, A Defense of the Constitutions of Government of the United States of America, Renewable energy

Trilateral North American initiative will lead first case study for IRENA global platform supporting transition to renewable energy for remote, rural and Indigenous communities worldwide.

Key Points: 
  • Trilateral North American initiative will lead first case study for IRENA global platform supporting transition to renewable energy for remote, rural and Indigenous communities worldwide.
  • For the first time ever, the three parties, through the Commission for Environmental Cooperation ( CEC ), are engaged in trilateral work to help support these communities in their transition to renewable energy.
  • During an event on Indigenous community-led global renewable energy microgrids hosted by the Canadian-based Indigenous Clean Energy (ICE) social enterprise, IRENA and Natural Resources Canada jointly launched the global initiative alongside the announcement of a C$500,000 founding investment from the Government of Canada in the global platform.
  • The Global Initiative is a multi-stakeholder platform for transitioning isolated and remote communities to renewable energy who are often reliant on diesel-based mini-grids for their electricity.

2nd Annual Action Forum to Bring Together Global, National, and Local Leaders Addressing Loneliness and Social Isolation

Retrieved on: 
Thursday, September 30, 2021
Connection, ACL, Degenerative disease, Brigham Young University, Depression, Substance abuse, COVID-19, Multimedia, Psychology, Global Initiative, HHS, Internal Revenue Code, Public health, Center, Grammatical mood, Prevalence, Social isolation, Loneliness, Technology, Obesity, Innovation, Anxiety, Smoking, Foundation, Social connection, Education, Public relations, Pharmaceutical industry

WASHINGTON, Sept. 30, 2021 /PRNewswire/ --Next week, the Foundation for Social Connection (F4SC), the nation's leading 501c3 nonprofit organization dedicated to developing and implementing evidence-based models to address social isolation and loneliness, will host the second annual End Social Isolation and Loneliness Action Forum (October 7-8).

Key Points: 
  • WASHINGTON, Sept. 30, 2021 /PRNewswire/ --Next week, the Foundation for Social Connection (F4SC), the nation's leading 501c3 nonprofit organization dedicated to developing and implementing evidence-based models to address social isolation and loneliness, will host the second annual End Social Isolation and Loneliness Action Forum (October 7-8).
  • "Loneliness and social isolation rival obesity and smoking in terms of their health risk," said Edward Garcia, Founder and Executive Director of F4SC.
  • "Given the impact of Covid-19, it's more important than ever that we have effective and data-driven models to enhance peoples' social connections."
  • This year's event brings together an array of interdisciplinary leaders focused on developing meaningful and actionable insights to address the increasing public health effects of social isolation.

Pulmonx Announces Two Additional Significant Blue Cross Blue Shield Plans Now Provide Coverage for Severe Emphysema/COPD Treatment

Retrieved on: 
Tuesday, September 21, 2021
Biotechnology, General Health, Health, Medical Devices, Degenerative disease, Adoption, Securities Act of 1933, BCBS, Henry Ford, Lung, Amerigroup, Security (finance), Drug Quality and Security Act, NASDAQ, U.S. Securities and Exchange Commission, FDA, Patient, Atmosphere, Global Initiative, MD, Chronic obstructive pulmonary disease, Corporation, GOLD, Blue Cross Blue Shield Association, Zephyr, Respiratory disease, Blues, Bronchoscopy, North Carolina, Securities Exchange Act of 1934, Health Care Service Corporation, North Dakota, Endobronchial valve, COPD, Safety, Han Lifei (d. 1424), Quality of life, SEC, Health insurance, Medical imaging, the Zephyr Valve Treatment, Pulmonx Corporation, THE ZEPHYR VALVE TREATMENT, PULMONX CORPORATION

This follows similar coverage decisions by other BCBS plans and now establishes positive coverage with the majority of BCBS covered members in the US (for an aggregate of 69 million covered lives).

Key Points: 
  • This follows similar coverage decisions by other BCBS plans and now establishes positive coverage with the majority of BCBS covered members in the US (for an aggregate of 69 million covered lives).
  • The Zephyr Valves are placed by bronchoscopy and are the first minimally invasive treatment option for patients who remain symptomatic despite medication and oxygen therapies.
  • The Zephyr Valve is a minimally invasive treatment option for severe COPD/emphysema, a chronic, progressive, and irreversible lung disease characterized by the destruction of lung tissue.
  • Pulmonx Corporation (NASDAQ: LUNG) is a global leader in minimally invasive treatments for severe lung disease.

MagGrow Wins The THRIVE | Bayer Sustainability Challenge

Retrieved on: 
Thursday, September 16, 2021
Water, Global Initiative, U.N, Agtech, Environment, Solution, Goal, SVG, TOP, Partnership, Farmer, Crop protection, Fine chemical, Agriculture

DUBLIN, Sept. 16, 2021 /PRNewswire/ --SVG Ventures | THRIVE and Bayer have announced that MagGrow , the company behind the patented, proprietary technology that is reducing waste associated with conventional pesticide spray applications, has won the THRIVE | Bayer Sustainability Challenge "Sustainable Scaleup Award."

Key Points: 
  • DUBLIN, Sept. 16, 2021 /PRNewswire/ --SVG Ventures | THRIVE and Bayer have announced that MagGrow , the company behind the patented, proprietary technology that is reducing waste associated with conventional pesticide spray applications, has won the THRIVE | Bayer Sustainability Challenge "Sustainable Scaleup Award."
  • MagGrow is one of three winners chosen from a global pool of approximately 300 applicants from across 57 countries.
  • The THRIVE | Bayer Sustainability Challenge aims to identify and support key start up and scaleup innovators like MagGrow in implementing solutions that promote sustainability.
  • The THRIVE | Bayer Sustainability Challenge combines Bayer Crop Sciences' sustainability commitments and THRIVE's Global Initiative focus on the U.N.

Fixed-Dose Combination of Albuterol and Budesonide (PT027) Demonstrated Significant Benefits for Asthma Patients in MANDALA and DENALI Phase III Trials

Retrieved on: 
Thursday, September 9, 2021
Biotechnology, Other Health, Health, Pharmaceutical, Clinical Trials

The trial included 3,132 patients with moderate to severe asthma taking maintenance ICS with or without additional controller medicines.

Key Points: 
  • The trial included 3,132 patients with moderate to severe asthma taking maintenance ICS with or without additional controller medicines.
  • Inflammation is a distinctive feature of asthma and plays a key role in asthma symptoms, exacerbations and deaths.
  • Many millions of patients globally rely on their rescue inhaler to alleviate acute symptoms, but this does not treat the underlying inflammation in asthma.
  • The MANDALA and DENALI trials demonstrate an albuterol/budesonide rescue inhaler can address inflammation and prevent exacerbations, making PT027 an important potential new treatment option for patients.

Pulmonx Announces Anthem Blue Cross Blue Shield Now Provides Coverage for Severe COPD/Emphysema Treatment

Retrieved on: 
Friday, August 20, 2021
Medical Devices, Insurance, Hospitals, Clinical Trials, Professional Services, Other Health, Biotechnology, Managed Care, General Health, Health, SEC, COPD, Securities Act of 1933, Safety, Endobronchial valve, Lung, Atmosphere, GOLD, Securities Exchange Act of 1934, University, U.S. Securities and Exchange Commission, Policy, Health Care Service Corporation, Â, Breathe Me, Blues, Degenerative disease, Respiratory disease, Quality of life, Drug Quality and Security Act, Adoption, BCBS, Valve, NASDAQ, Chronic obstructive pulmonary disease, FDA, Security (finance), Oxygen, Corporation, LVRS, Global Initiative, Interventional pulmonology, Bronchoscopy, Han Lifei (d. 1424), Patient, Medical imaging, the Zephyr Valve Treatment, Pulmonx Corporation, THE ZEPHYR VALVE TREATMENT, PULMONX CORPORATION

Pulmonx Corporation (Nasdaq: LUNG) (Pulmonx), a global leader in minimally invasive treatments for severe lung disease, today announced that Anthem Blue Cross Blue Shield (BCBS) has issued a positive coverage policy for endobronchial valves, including Pulmonxs Zephyr Valve, for severe emphysema, a form of COPD.

Key Points: 
  • Pulmonx Corporation (Nasdaq: LUNG) (Pulmonx), a global leader in minimally invasive treatments for severe lung disease, today announced that Anthem Blue Cross Blue Shield (BCBS) has issued a positive coverage policy for endobronchial valves, including Pulmonxs Zephyr Valve, for severe emphysema, a form of COPD.
  • This follows similar coverage decisions by other BCBS plans and brings the total BCBS covered members in the US to 59 million.
  • Not surprisingly, the policy cites our published data, which demonstrate the safety, effectiveness and long-term positive patient outcomes of our Zephyr valve treatment."
  • The Zephyr Valve is a minimally invasive treatment option for severe COPD/emphysema, a chronic, progressive, and irreversible lung disease characterized by the destruction of lung tissue.